- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic myeloid leukaemia
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 944KB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 185KB)
Asciminib – July 2022
Asciminib: Tablet 20 mg, Tablet 40 mg; Scemblix®
Last updated
11 November 2022